Cerus Expands INTERCEPT Distribution Network.-- Chile, Indonesia and Poland Added -- CONCORD, Calif. -- Cerus Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CERS) announced that the company has entered exclusive agreements with key distributors to supply the INTERCEPT Blood System for platelet and plasma in Chile, Indonesia and Poland. These new distributor relationships broaden the company's access to markets for the INTERCEPT Blood System, which is already marketed in over 30 countries in Europe, Asia and the Middle East. "These new distribution agreements highlight the growing market demand for the INTERCEPT Blood System to inactivate in·ac·ti·vate v. 1. To render nonfunctional. 2. To make quiescent. in·ac  ti·va harmful
pathogens that may be present in donated blood," said Claes
Glassell, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cerus Corporation. "I am pleased to
have established business relationships in Chile, Indonesia and Poland
in keeping with our global commercialization strategy. Together, these
new regions represent an estimated $25 million of new market opportunity
for the INTERCEPT platelet and plasma systems."
In July 2007, Cerus announced that the company is collaborating with Grifols S.A. to supply the INTERCEPT Blood System for platelets and plasma in Spain and Portugal. Based on the early success of this relationship, Cerus and Grifols have mutually agreed to expand the INTERCEPT Blood System marketing effort into Chile. Grifols has had commercial operations in Chile since 1992, with local headquarters in Santiago. Cerus granted PT Medquest Jaya Global distribution rights in Indonesia as a collaboration to improve blood safety in Indonesia. Medquest is a leader for innovative blood safety technology distribution in Indonesia and other countries in Asia. Medquest supports key customers, including the Indonesian Red Cross, Indonesian hospitals and U.S. Naval Medical Research. The Indonesian Red Cross oversees a blood banking system consisting of 189 blood centers. In Poland, Hemosystems Sobczak & Co has agreed to distribute the INTERCEPT Blood System. Hemosystems is based in Warsaw and specializes in the distribution of devices and disposables to the blood transfusion blood transfusion, transfer of blood from one person to another, or from one animal to another of the same species. Transfusions are performed to replace a substantial loss of blood and as supportive treatment in certain diseases and blood disorders. market. ABOUT CERUS Cerus Corporation is a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens blood-borne pathogens, n.pl pathogenic microorganisms that are present in human blood and cause disease in humans. blood-borne pathogens exposure control plan, n in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The Company is also pursuing regulatory approvals in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and other countries. The INTERCEPT red blood cell red blood cell: see blood. system is currently in clinical development. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements including references to the commercial acceptance of the INTERCEPT Blood System. Words such as "believe," "should," "expect" and similar words or expressions or the negative of these words or expressions are intended to identify forward-looking statements. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the commercialization and market acceptance of the INTERCEPT Blood System, as well as other risks detailed in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 2007, and Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the three months ended March 31, 2008. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion